Company news
Crispr Therapeutics Ag (NASDAQ:CRSP) news
Crispr Therapeutics Ag news releases on 6ix. Latest, Oct 2, 2026: CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel)…
Press releases & updates
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
October 2, 2026
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
October 1, 2026
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
September 8, 2026
CRISPR Therapeutics Presents Phase 1a Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
August 31, 2026
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
August 28, 2026
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
August 3, 2026
CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference
May 6, 2026
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
May 4, 2026
Arrayed CRISPR Screening Market Presents Lucrative Opportunities Through 2026-2030: Total Revenue to Grow by $1.64 Billion at 17.7% CAGR
April 20, 2026
CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
April 6, 2026
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
March 10, 2026
CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering
March 9, 2026
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
February 12, 2026
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
February 11, 2026
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
January 12, 2026
CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 4, 2026
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
December 21, 2025
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
November 9, 2025
CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
November 7, 2025
CRISPR Therapeutics Presents New Preclinical Data for CTX460 Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency Utilizing Novel SyNTase Editing Platform
October 13, 2025
CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform
October 9, 2025
CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
September 30, 2025
CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe
September 21, 2025
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025
September 8, 2025
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
September 1, 2025
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
August 3, 2025
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer
July 1, 2025
CRISPR Therapeutics Named to TIME’s Most Influential Companies List of 2025
June 29, 2025
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline
June 25, 2025
CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies
May 18, 2025
CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3
May 5, 2025
CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
April 2, 2025
CRISPR Therapeutics Announces Transition of Chief Operating Officer
March 25, 2025
CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
February 25, 2025
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
February 10, 2025
CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
January 28, 2025
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones
January 12, 2025
CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 7, 2025
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
January 6, 2025
CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
December 8, 2024
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
November 13, 2024
CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
November 6, 2024
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
November 4, 2024
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
August 4, 2024
CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
May 22, 2024
CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
May 8, 2024
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
May 7, 2024
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach
May 7, 2024
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
April 21, 2024
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
April 2, 2024